Methamphetamine Pharmacotherapy: A Need to Re-focus on the Complex Neurobiological Changes that Occur Both During and After Methamphetamine Use Disorder

Treatment for methamphetamine use disorder (MUD) has traditionally relied on psychosocial interventions, which face significant barriers regarding accessibility and patient retention. In response, research has attempted to develop pharmacological maintenance therapies modeled after successful opioid treatments (e.g., methadone or buprenorphine). The premise was to use prescription stimulants to substitute for illicit methamphetamine, thereby reducing withdrawal symptoms and craving. However, this meta-analysis of current evidence indicates that these approaches have had limited success. Furthermore, there are ongoing concerns regarding the potential for toxic interactions if prescription stimulants are co-consumed with illicit methamphetamine.

The authors argue that the field must move beyond simple maintenance models. MUD is a chronic, relapsing condition characterized by profound neurobiological adaptations, including the down-regulation of dopamine and serotonin systems, persistent neuro-inflammation, and structural brain changes. Because current substitution therapies do not address these specific underlying neurobiological mechanisms, they fail to significantly improve long-term abstinence or functional recovery. A more effective strategy would involve pharmacotherapies specifically designed to manage the acute withdrawal phase and the protracted post-acute recovery period.

To improve treatment outcomes, future pharmacotherapeutic development should prioritize targets that address the core pathology of MUD. This includes modulating stress-response systems like corticotrophin-releasing factor (CRF), mitigating neuro-inflammatory and oxidative stress pathways that contribute to neurotoxicity, and targeting the glutamate-driven neuroplastic changes that underpin drug craving. By focusing on these mechanisms, researchers may be able to develop treatments that go beyond merely substituting for the drug, instead promoting genuine neural restoration, improving cognitive function, and effectively reducing the risk of relapse.